Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Scn1a gene restoration and functional rescue in mouse and human neuronal models of Dravet syndrome
FY 2022-23
Summary
Supervisor: Yang Zhou, Montreal Neurological Institute
Dravet Syndrome (DS) is a severe neurodevelopmental disorder that is characterized by infantile-onset, prolonged, drug-resistant seizures, which cause a high rate of sudden unexpected death in epilepsy. Patients with DS often suffer from compromised cognitive, learning and behavioural performance, manifest Autism-related characteristics and delayed development. More than 70% of DS result from SCN1A haploinsufficiency, a genetic condition in which deletion or truncation occurs in one of the two copies of a gene, causing loss of function. The SCN1A gene encodes the alpha subunit of the voltage-gated sodium channel (Nav1.1) that is enriched in inhibitory and other types of neurons, and precisely controls the excitability of neuronal networks in the brain. SCN1A haploinsufficiency leads to only 50% of the normal functional form of SCN1A protein being expressed in the brain, which causes epilepsy as a result of impaired neuronal inhibition. Currently, there are no effective treatments that can cure DS or manage life-threatening epilepsies in patients. Towards the goal of developing translational approaches and therapeutic applications for DS, we engineered novel AAV vectors which contain compact-sized CRISPR/dCas9 transcriptional activators, that allow for augmenting the expression of targeted genes of interest. In this project, we plan to leverage AAV-mediated gene delivery and CRISPR-based strategies to test the proof-of-concept of gene-based therapy for DS in experimental models. We aim to restore Scn1a gene expression and rescue molecular and neuronal deficits in mouse models as well as human neuron models of DS using our engineered CRISPR and AAV platforms. This project will provide in-depth neurobiological insights into the functional rescue of DS and pave the foundation for developing and translating CRISPR/dCas9-based therapeutic options for Dravet syndrome in Canada and worldwide.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475826
Name
Suresh Rahul
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Scn1a gene restoration and functional rescue in mouse and human neuronal models of Dravet syndrome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adeno-Associated Virus; Autism Spectrum Disorder; Crispr/Cas9; Dravet Syndrome; Haploinsufficiency; Hipsc-Derived Neuronal Models; Mouse Models; Nervous System; Neurodevelopmental Disorders; Scn1a
Abstract
Supervisor: Yang Zhou, Montreal Neurological Institute
Dravet Syndrome (DS) is a severe neurodevelopmental disorder that is characterized by infantile-onset, prolonged, drug-resistant seizures, which cause a high rate of sudden unexpected death in epilepsy. Patients with DS often suffer from compromised cognitive, learning and behavioural performance, manifest Autism-related characteristics and delayed development. More than 70% of DS result from SCN1A haploinsufficiency, a genetic condition in which deletion or truncation occurs in one of the two copies of a gene, causing loss of function. The SCN1A gene encodes the alpha subunit of the voltage-gated sodium channel (Nav1.1) that is enriched in inhibitory and other types of neurons, and precisely controls the excitability of neuronal networks in the brain. SCN1A haploinsufficiency leads to only 50% of the normal functional form of SCN1A protein being expressed in the brain, which causes epilepsy as a result of impaired neuronal inhibition. Currently, there are no effective treatments that can cure DS or manage life-threatening epilepsies in patients. Towards the goal of developing translational approaches and therapeutic applications for DS, we engineered novel AAV vectors which contain compact-sized CRISPR/dCas9 transcriptional activators, that allow for augmenting the expression of targeted genes of interest. In this project, we plan to leverage AAV-mediated gene delivery and CRISPR-based strategies to test the proof-of-concept of gene-based therapy for DS in experimental models. We aim to restore Scn1a gene expression and rescue molecular and neuronal deficits in mouse models as well as human neuron models of DS using our engineered CRISPR and AAV platforms. This project will provide in-depth neurobiological insights into the functional rescue of DS and pave the foundation for developing and translating CRISPR/dCas9-based therapeutic options for Dravet syndrome in Canada and worldwide.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Suresh, Rahul
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~